Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRR | Q9GZT4 | 4/20 | 1.00 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.80 |
| ▸ | PPARG | P37231 | 14/20 | 0.57 |
| ▸ | PPARA | Q07869 | 12/20 | 0.57 |
| ▸ | ALPI | P09923 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | XIAP | P98170 | 1/20 | 0.57 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.57 |
| ▸ | ACE | P12821 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aminooxyphenylpropionate SCHEMBL1520985 | 1.00 | SRR (1.00) | SRRPSAT1PPARGPPARAALPI | |
| Aminooxyphenylpropionate SCHEMBL6513696 | 1.00 | SRR (1.00) | SRRPSAT1PPARGPPARAALPI | |
| Aminooxyphenylpropionate SCHEMBL1357763 | 0.98 | SRR (0.96) | SRRPSAT1PPARGPPARAALPI | |
| SCHEMBL15446238 | 0.89 | SRR (1.00) | SRRPSAT1PPARGPPARA | |
| SCHEMBL15446229 | 0.86 | SRR (0.75) | SRRPSAT1PPARGPPARA | |
| SCHEMBL288435 | 0.86 | PPARA (0.74) | SRRPSAT1PPARGPPARA | |
| SCHEMBL11298237 | 0.85 | SRR (0.73) | SRRPSAT1PPARGPPARASLC7A5 | |
| SCHEMBL15446294 | 0.83 | SRR (0.71) | SRRPSAT1PPARGPPARA | |
| SCHEMBL15446243 | 0.83 | SRR (0.71) | SRRPSAT1PPARGPPARA | |
| Bromide SCHEMBL11297122 | 0.83 | SRR (0.71) | SRRPSAT1PPARGPPARASLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2227233-B1 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2013-02-13 | — | — | EP | claimed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | claimed |
| EP-2227233-A2 | IDO INHIBITORS | Newlink Genetics (US) | 2010-09-15 | — | — | EP | claimed |
| WO-2009073620-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-06-11 | — | — | WO | claimed |
| US-7435716-B2 | Compounds pharmaceutical compositions and methods for treatment of bacteremia and/or septicemia | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2008-10-14 | — | — | US | claimed |
| US-20040082505-A1 | Compounds pharmaceutical compositions and methods for treatment of bacteremia and/or septicemia | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2004-04-29 | — | — | US | claimed |
| EP-1351992-A2 | HYBRID PEPTIDES FOR TREATMENT OF BACTEREMIA AND SEPTICEMIA | Ramot at Tel Aviv University Ltd. (IL) | 2003-10-15 | — | — | EP | claimed |
| WO-2002055543-A2 | HYBRID PEPTIDES FOR TREATMENT OF BACTEREMIA AND SEPTICEMIA | UNIV RAMOT (IL) | 2002-07-18 | — | — | WO | claimed |
| EP-0008494-B1 | METHOD OF IMPROVING OR MAINTAINING DIGESTIBILITY OF FODDER CROPS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-12-22 | — | — | EP | claimed |
| US-4304592-A | Method of improving or maintaining digestibility of fodder crops | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1981-12-08 | — | — | US | claimed |
| EP-0008494-A1 | Method of improving or maintaining digestibility of fodder crops | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1980-03-05 | — | — | EP | claimed |
| US-20260139264-A1 | Compositions And Methods For Production Of Salidroside, Icariside D2, And Precursors Of Salidroside And Icariside D2 | WHITEHEAD INST FOR BIOMEDICAL RESEARCH (US) | 2026-05-21 | — | — | US | disclosed |
| US-12385055-B2 | Compositions and methods for production of salidroside, icariside D2, and precursors of salidroside and icariside D2 | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2025-08-12 | — | — | US | disclosed |
| US-20230058465-A1 | Compositions And Methods For Production Of Salidroside, Icariside D2, And Precursors Of Salidroside And Icariside D2 | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2023-02-23 | — | — | US | disclosed |
| US-11408009-B2 | Host cell expression of 4-hydroxyphenylacetaldehyde synthase for production of salidroside, icariside D2, and precursors | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-08-09 | — | — | US | disclosed |
| EP-0406760-B1 | Plant growth regulating composition | SUMITOMO CHEMICAL CO (JP) | 1994-10-05 | — | — | EP | disclosed |
| EP-0406760-A1 | Plant growth regulating composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-01-09 | — | — | EP | disclosed |
| US-4423213-A | ANTIBIOTIC | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-12-27 | — | — | US | disclosed |
| EP-0008494-B1 | METHOD OF IMPROVING OR MAINTAINING DIGESTIBILITY OF FODDER CROPS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-12-22 | — | — | EP | disclosed |
| US-4304592-A | Method of improving or maintaining digestibility of fodder crops | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1981-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053941-A1 | IDO Inhibitors | IDO1, IDO2, INMT | SRR 527/4885PSAT1 1058/4885PPARG 4755/4885 |
| US-20260139264-A1 | Compositions And Methods For Production Of Salidroside, Icariside D2, And Precursors Of Salidroside And Icariside D2 | COMT, UGDH, GUSB | SRR 911/4885PSAT1 27/4885PPARG 3083/4885 |
| US-20040082505-A1 | Compounds pharmaceutical compositions and methods for treatment of bacteremia and/or septicemia | CD14, SELP, C5AR1 | SRR 1730/4885PSAT1 1202/4885PPARG 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.